Hydration, IV Infusions, Injections and Vaccine Charge Process

Size: px
Start display at page:

Download "Hydration, IV Infusions, Injections and Vaccine Charge Process"

Transcription

1 There are a number of items to be considered when billing for the Nursing service to perform drug therapy, the charge process is divided into three specific groups of codes and processes. 1. Hydration and IV Therapy 2. Injections into IV lines and intramuscular 3. Vaccines Hydration and IV Therapy: Hydration and IV therapy are time based charges, which have a first hour and a subsequent hour. The codes are as follows: Intravenous infusion, hydration; initial, 31 minutes to 1 hour Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure), the additional time has to be greater than 30 minutes Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour, minutes (less than 16 min = IVP) Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure) Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion, up to 1 hour (List separately in addition to code for primary procedure), minutes and a different drug Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure), once per encounter Subcutaneous infusion for therapy or prophylaxis (specify substance or drug); initial, up to 1 hour, including pump set up and establishment of subcutaneous infusion site(s), minutes Subcutaneous infusion for therapy or prophylaxis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure), must be greater than 30 minutes Subcutaneous infusion for therapy or prophylaxis (specify substance or drug); additional pump set up with establishment of new subcutaneous infusion site(s) (List separately in addition to code for primary procedure), once per encounter Hydration therapy must last longer than 30 minutes, to be considered for an initial 1 st hour code. IV therapy less than 16 minutes is to be coded as an IV injection. Hydration less than 30 minutes is not a billable procedure. Establishing a heparin or saline lock for access or a slow drip of saline for access is not hydration or IV therapy. PARA Healthcare Financial Services March 2012 Page 1

2 Injections into IV lines are required to be classed into the following codes: 1. Initial injection med A (96374) 2. Additional subsequent injection, meds B Z (96375) 3. Additional subsequent injections med A (96376), there must be a period of more than 30 minutes that has to pass between injections of same drug. The codes used for IV injections are as follows: Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure) Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure) see time note above Intramuscular, subcutaneous and intra arterial injections use the following codes: Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intra arterial Vaccines are based on the number of injections and for Medicare the type of vaccine: Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); one vaccine (single or combination vaccine/toxoid) Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) G0008 / G9141 ADMINISTRATION OF INFLUENZA VIRUS / H1N1 VACCINE G0009 ADMINISTRATION OF PNEUMOCOCCAL VACCINE G0010 ADMINISTRATION OF HEPATITIS B VACCINE not billable hospital outpatient Part B PARA Healthcare Financial Services March 2012 Page 2

3 General rules: There can only be one initial procedure, on a claim / encounter. The ranking to determine the initial procedure is as follows, the remaining procedures must be coded as additional or subsequent. 1. Chemotherapy services 2. IV therapy 1 st hour IV injection initial 4. Any other infusion/iv therapy code precedes a hydration code Hydration 1 st hour this code used as initial only if NO OTHER drug is administered as an infusion or IV therapy Establishing IV access is not hydration or IV therapy. Hydration procedures must have a diagnosis supporting the procedure, hydration substances include normal saline, D5W, and pre packaged KCL. Initial IV therapy must last longer than 15minutes, but if less than 16 minutes, the procedure should be charged as an IV injection. Drug admin charges are only reported on outpatient/ambulatory care, emergency and observation patients, the service is not charged on inpatients. There are a number of different revenue codes which can be used to report these services; the basic guideline is to list the charge against the nursing station providing the service. For the charge for an additional hour of hydration or IV med therapy the service must last for more than 30 minutes into the additional hour IV Therapy General Classification 0450 Emergency Room General Classification 0456 Emergency Room Urgent Care 0510 Clinic General Classification 0516 Clinic Urgent Care Clinic 0761 Treatment or Observation Room Treatment Room 0762 Treatment or Observation Room Observation Room 0940 Other Therapeutic Services General Classification PARA Healthcare Financial Services March 2012 Page 3

4 General rules (continued): If performed to facilitate the infusion or injection, the following services are included and are not reported separately referenced in AMA CPT Nomenclature: 1. Use of local anesthesia 2. IV start 3. Access to indwelling IV, subcutaneous catheter or port 4. Flush at conclusion of infusion 5. Standard tubing, syringes, and supplies For Declotting of a catheter or port, use The definition of when a chemo code is to be billed instead of an IV med therapy is a function of the requirements of the drug preparation and the Nurse performing the procedure. A quote from AMA CPT: See codes for the administration of chemotherapy or other highly complex drug or highly complex biologic agent services. These highly complex services require advanced practice training and competency for Staff who provide these services; special consideration for the preparation, dosage or disposal; and commonly, these services entail significant patient risk and frequent monitoring. Examples are frequent changes in the infusion rate, prolonged presence of nurse administering the solution for patient monitoring and infusion adjustments, and frequent conferring with the physician about these issues. PARA Healthcare Financial Services March 2012 Page 4

5 Vaccines: The codes associated with vaccine administration are as follows: These codes are for the Nursing service, the drug costs are to be attached to the product codes , sample pasted below. PARA Healthcare Financial Services March 2012 Page 5

6 Complex drugs and biologic agents are to be billed using the chemotherapy codes: Chemotherapy administration, subcutaneous or intramuscular; non hormonal anti neoplastic Chemotherapy administration, subcutaneous or intramuscular; hormonal anti neoplastic Chemotherapy administration; intralesional, up to and including 7 lesions Chemotherapy administration; intralesional, more than 7 lesions Chemotherapy administration; intravenous, push technique, single or initial substance/drug Chemotherapy administration; intravenous, push technique, each additional substance/drug (List separately in addition to code for primary procedure) Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure) Chemotherapy administration, intravenous infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a portable or implantable pump Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure) Chemotherapy administration, intra arterial; push technique Chemotherapy administration, intra arterial; infusion technique, up to 1 hour Chemotherapy administration, intra arterial; infusion technique, each additional hour (List separately in addition to code for primary procedure) Chemotherapy administration, intra arterial; infusion technique, initiation of prolonged infusion (more than 8 hours), requiring the use of a portable or implantable pump Chemotherapy administration into pleural cavity, requiring and including thoracentesis Chemotherapy administration into peritoneal cavity via indwelling port or catheter Chemotherapy administration, into CNS (eg, intrathecal), requiring and including spinal puncture PARA Healthcare Financial Services March 2012 Page 6

7 Drugs and Biologicals related to Chemotherapy Table A. Limited coverage is being established by CMS for these drugs on List A C9257 INJECTION, BEVACIZUMAB, 0.25 MG J0894 INJECTION, DECITABINE, 1 MG J9001 INJECTION, DOXORUBICIN HYDROCHLORIDE, ALL LIPID FORMULATIONS, 10 MG J9010 INJECTION, ALEMTUZUMAB, 10 MG J9015 INJECTION, ALDESLEUKIN, PER SINGLE USE VIAL J9017 INJECTION, ARSENIC TRIOXIDE, 1 MG J9025 INJECTION, AZACITIDINE, 1 MG J9033 INJECTION, BENDAMUSTINE HCL, 1 MG J9035 INJECTION, BEVACIZUMAB, 10 MG J9041 INJECTION, BORTEZOMIB, 0.1 MG J9043 INJECTION, CABAZITAXEL, 1 MG J9171 INJECTION, DOCETAXEL, 1 MG J9179 INJECTION, ERIBULIN MESYLATE, 0.1 MG J9201 INJECTION, GEMCITABINE HYDROCHLORIDE, 200 MG J9206 INJECTION, IRINOTECAN, 20 MG J9207 INJECTION, IXABEPILONE, 1 MG J9214 INJECTION, INTERFERON, ALFA 2B, RECOMBINANT, 1 MILLION UNITS J9228 INJECTION, IPILIMUMAB, 1 MG J9263 INJECTION, OXALIPLATIN, 0.5 MG J9264 INJECTION, PACLITAXEL PROTEIN BOUND PARTICLES, 1 MG J9265 INJECTION, PACLITAXEL, 30 MG J9302 INJECTION, OFATUMUMAB, 10 MG J9305 INJECTION, PEMETREXED, 10 MG J9310 INJECTION, RITUXIMAB, 100 MG J9330 INJECTION, TEMSIROLIMUS, 1 MG J9351 INJECTION, TOPOTECAN, 0.1 MG J9395 INJECTION, FULVESTRANT, 25 MG J9999 NOT OTHERWISE CLASSIFIED, ANTINEOPLASTIC DRUGS PARA Healthcare Financial Services March 2012 Page 7

8 Drugs and Biologicals related to Chemotherapy (continued) Table B. The FI/Contractor expects the use of these drugs on List B will be reasonable and necessary J9000 INJECTION, DOXORUBICIN HYDROCHLORIDE, 10 MG J9020 INJECTION, ASPARAGINASE, 10,000 UNITS J9027 INJECTION, CLOFARABINE, 1 MG J9031 BCG (INTRAVESICAL) PER INSTILLATION J9040 INJECTION, BLEOMYCIN SULFATE, 15 UNITS J9045 INJECTION, CARBOPLATIN, 50 MG J9050 INJECTION, CARMUSTINE, 100 MG J9055 INJECTION, CETUXIMAB, 10 MG J9060 INJECTION, CISPLATIN, POWDER OR SOLUTION, 10 MG J9065 INJECTION, CLADRIBINE, PER 1 MG J9070 CYCLOPHOSPHAMIDE, 100 MG J9098 INJECTION, CYTARABINE LIPOSOME, 10 MG J9100 INJECTION, CYTARABINE, 100 MG J9120 INJECTION, DACTINOMYCIN, 0.5 MG J9130 DACARBAZINE, 100 MG J9150 INJECTION, DAUNORUBICIN, 10 MG J9151 INJECTION, DAUNORUBICIN CITRATE, LIPOSOMAL FORMULATION, 10 MG J9160 INJECTION, DENILEUKIN DIFTITOX, 300 MICROGRAMS PARA Healthcare Financial Services March 2012 Page 8

9 Drugs and Biologicals related to Chemotherapy (Table B continued) J9165 INJECTION, DIETHYLSTILBESTROL DIPHOSPHATE, 250 MG J9178 INJECTION, EPIRUBICIN HCL, 2 MG J9181 INJECTION, ETOPOSIDE, 10 MG J9185 INJECTION, FLUDARABINE PHOSPHATE, 50 MG J9190 INJECTION, FLUOROURACIL, 500 MG J9200 INJECTION, FLOXURIDINE, 500 MG J9208 INJECTION, IFOSFAMIDE, 1 GRAM J9209 INJECTION, MESNA, 200 MG J9211 INJECTION, IDARUBICIN HYDROCHLORIDE, 5 MG J9215 INJECTION, INTERFERON, ALFA N3, (HUMAN LEUKOCYTE DERIVED), 250,000 IU J9230 INJECTION, MECHLORETHAMINE HYDROCHLORIDE, (NITROGEN MUSTARD), 10 MG J9245 INJECTION, MELPHALAN HYDROCHLORIDE, 50 MG J9250 METHOTREXATE SODIUM, 5 MG J9260 METHOTREXATE SODIUM, 50 MG J9261 INJECTION, NELARABINE, 50 MG J9266 INJECTION, PEGASPARGASE, PER SINGLE DOSE VIAL J9268 INJECTION, PENTOSTATIN, 10 MG J9270 INJECTION, PLICAMYCIN, 2.5 MG PARA Healthcare Financial Services March 2012 Page 9

10 Drugs and Biologicals related to Chemotherapy (Table B continued) J9280 MITOMYCIN, 5 MG J9293 INJECTION, MITOXANTRONE HYDROCHLORIDE, PER 5 MG J9300 INJECTION, GEMTUZUMAB OZOGAMICIN, 5 MG J9303 INJECTION, PANITUMUMAB, 10 MG J9320 INJECTION, STREPTOZOCIN, 1 GRAM J9340 INJECTION, THIOTEPA, 15 MG J9357 INJECTION, VALRUBICIN, INTRAVESICAL, 200 MG J9360 INJECTION, VINBLASTINE SULFATE, 1 MG J9370 VINCRISTINE SULFATE, 1 MG J9390 INJECTION, VINORELBINE TARTRATE, 10 MG J9600 INJECTION, PORFIMER SODIUM, 75 MG PARA Healthcare Financial Services March 2012 Page 10

11 Drugs and Biologicals outside the 9000 range Table C. These drugs can be billed with Chemo Administration codes J0128 INJECTION, ABARELIX, 10 MG J0215 INJECTION, ALEFACEPT, 0.5 MG J0970 INJECTION, ESTRADIOL VALERATE, UP TO 40 MG J1000 INJECTION, DEPO ESTRADIOL CYPIONATE, UP TO 5 MG J1380 INJECTION, ESTRADIOL VALERATE, UP TO 10 MG J1390 INJECTION, ESTRADIOL VALERATE, UP TO 20 MG J1410 INJECTION, ESTROGEN CONJUGATED, PER 25 MG J1435 INJECTION, ESTRONE, PER 1 MG J3315 INJECTION, TRIPTORELIN PAMOATE, 3.75 MG J7516 CYCLOSPORIN, PARENTERAL, 250 MG J7525 TACROLIMUS, PARENTERAL, 5 MG J9355 INJECTION, TRASTUZUMAB, 10 MG Q3025 INJECTION, INTERFERON BETA 1A, 11 MCG FOR INTRAMUSCULAR USE PARA Healthcare Financial Services March 2012 Page 11

12 Billing Examples Service Billing Codes Billing Code Description 1. Patient receives a saline/hep lock for access None Insertion of an access site catheter does not create a billable event 2. Patient receives infusion TKO at a rate of 100 ml/hr for a period of 2 hours None Infusion of a fluid for access TKO/KVO is not a billable event 3. Patient receives a hydration infusion "bolus" of less than 30 minutes None Hydration must last longer than 30 minutes to be billable 4. Patient receives a med infusion of less than 16 minutes Med infusions less than 16 minutes are to be billed as a IVP injection 5. Patient receives hydration of 89 minutes Patient is to be billed for 1 hour hydration, additional hours require greater than 30 minutes of additional time 6. Patient receives hydration for 45 minutes and a med injection into the IV line, there is not a medical condition to require the hydration If the hydration is only a method to admin the drug through the IV line the Patient should only be billed for the IV injection, but not the infusion 7. Patient receives hydration for 45 minutes and a med injection into the IV line, there is a medical condition to require the hydration If there is a medical requirement for the hydration, then both codes are billable, bill only one initial per encounter, IVP outranks hydration 8. Patient receives IV infusion for 91 minutes, on the 45th minute the Patient receives a 2nd med same site / line infusion for 45 minutes Patient is to be billed for 1st hour med infusion, additional hour infusion (greater than 30 minutes), and 1 hour concurrent med infusion PARA Healthcare Financial Services March 2012 Page 12

13 9. Patient receives IV infusion for 90 minutes, on the 91st minute the Patient receives a 2nd med same site for 45 minutes Patient is to be billed for 1st hour med infusion, and 1 hour sequential med infusion, 2nd hour infusion requires greater than 30 minutes 10. Patient receives IV infusion for 91 minutes, the Patient then receives a 2nd med, new site and pump for 45 minutes Patient is to be billed for 1st hour med infusion, add hour infusion, and 1 hour sequential med infusion new site 11. Patient receives med infusion for 45 minutes, and a 2nd drug is injected into the IV line Patient is to be billed for a IV med infusion, plus a IV injection, only one initial code per encounter 12. Patient receives med infusion for 45 minutes, and a 2nd drug is injection into the IV line, and then 31 minutes later the same drug is injected into the IV line Patient is to be billed for IV med infusion, injection of a drug into IV line, and then the same drug injected into a IV line, outside the 30 minute inclusion limit 13. Patient receives med infusion for 45 minutes, and a 2nd drug is injection into the IV line, and then 20 minutes later the same drug is injected into the IV line Patient is to be billed for IV med infusion, injection of a drug into IV line, because the same drug was injected within 30 minutes no additional code(s) 14. Patient receives med infusion for 45 minutes, and a 2nd drug is injected into the IV line, and then a 3rd drug is injected into the IV line x 2 Patient is to be billed for a IV med infusion, injection into a IV line, and sequential drug injection into a IV line 15. Patient is injected a pain med IM and then also a vaccine Patient is to be billed im injection and a vaccine admin injection 16. Patient is injected the same drug twice IM 15 minutes apart x 2 Patient is to be billed the im injection twice PARA Healthcare Financial Services March 2012 Page 13

Cost Differences in Cancer Care Across Settings

Cost Differences in Cancer Care Across Settings Cost Differences in Cancer Care Across Settings August 2013 THE MORAN COMPANY 1 Cost Differences in Cancer Care Across Settings In a prior memorandum, we presented evidence documenting the growing share

More information

Chemotherapy Administration, Hydration and Therapeutic, Prophylactic, and Diagnostic Injections and Infusions

Chemotherapy Administration, Hydration and Therapeutic, Prophylactic, and Diagnostic Injections and Infusions Chemotherapy Administration, Hydration and Therapeutic, Prophylactic, and Diagnostic Injections and Infusions Table of Contents: Overview... Professional Services... 2 Services... 4 Overview Chemotherapy

More information

MEDICAL CENTER ADMINISTRATIVE POLICY AND PROCEDURES SCOPE KFH Hospital, City Section No.

MEDICAL CENTER ADMINISTRATIVE POLICY AND PROCEDURES SCOPE KFH Hospital, City Section No. of 22 I. Purpose To establish safe medication practices for High Alert medications to maximize the safety of the medication processes associated with these medications. II. Policy. High alert medications

More information

MMA - 2005 Drug Administration Coding Revisions

MMA - 2005 Drug Administration Coding Revisions Related Change Request (CR) #: 3631 Related CR Release Date: December 10, 2004 Related CR Transmittal #: 129 Effective Date: January 1, 2005 Implementation Date: January 17, 2005 MMA - 2005 Drug Administration

More information

Documentation Summary for Chemotherapy Administration, Nonchemotherapy Injections and Infusions

Documentation Summary for Chemotherapy Administration, Nonchemotherapy Injections and Infusions Documentation Summary for Chemotherapy Administration, Nonchemotherapy Injections and Infusions Documentation to Support Medical Necessity of Chemotherapy Services Date: April 23, 2012 Source Information:

More information

Correct Coding for Infusions and Injections. Agenda. Supervision Levels. Regan Tyler, CPC, CPC-H, CPMA, CEMC, ACS-EM

Correct Coding for Infusions and Injections. Agenda. Supervision Levels. Regan Tyler, CPC, CPC-H, CPMA, CEMC, ACS-EM Correct Coding for Infusions and Injections Regan Tyler, CPC, CPC-H, CPMA, CEMC, ACS-EM 1 Agenda The hierarchy facility vs. clinic for infusion coding - Initial, each additional, each sequential, concurrent

More information

Eliminating Infusion Confusion. Agenda

Eliminating Infusion Confusion. Agenda Eliminating Infusion Confusion (Drug Administrations in Facility and Non-facility Settings) Presented by Maria Rita Genovese, CPC, PCS & Maryann C. Palmeter, CPC, CENTC 1 Agenda Review of CPT codes What

More information

Medications most likely to be seen in primary care

Medications most likely to be seen in primary care Hazardous Medicines The majority of medicines are not classed as hazardous. The only medicinal products that are automatically deemed to be hazardous are cytotoxic and cytostatic medicines. There is no

More information

GROUP 1 CARCINOGEN, CHEMOTHERAPY WASTE & OTHER HAZARDOUS DRUG DISPOSAL NAME APPROVAL DATE EFFECTIVE DATE REVISION RENEE MICHEL 05/01/11 0

GROUP 1 CARCINOGEN, CHEMOTHERAPY WASTE & OTHER HAZARDOUS DRUG DISPOSAL NAME APPROVAL DATE EFFECTIVE DATE REVISION RENEE MICHEL 05/01/11 0 GROUP 1 CARCINOGEN, CHEMOTHERAPY WASTE & OTHER HAZARDOUS DRUG DISPOSAL NAME APPROVAL DATE EFFECTIVE DATE REVISION RENEE MICHEL 05/01/11 0 INTRODUCTION Prior to commencing work involving carcinogens, chemotherapeutics

More information

Synagis (Palivizumab)

Synagis (Palivizumab) Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization

More information

Coding Injections and Infusions

Coding Injections and Infusions Coding Injections and Infusions Audio Seminar/Webinar January 31, 2008 Practical Tools for Seminar Learning Copyright 2008 American Health Information Management Association. All rights reserved. Disclaimer

More information

for Extended Stability Parenteral Drugs Third Edition Caryn M. Bing, R.Ph., M.S., FASHP Editor

for Extended Stability Parenteral Drugs Third Edition Caryn M. Bing, R.Ph., M.S., FASHP Editor Extended Stability for Parenteral Drugs Third Edition Editor Caryn M. Bing, R.Ph., M.S., FASHP 1 American Society of Health-System Pharmacists Bethesda, Maryland Contents Preface Acknowledgments x/ Dedication

More information

MASCC/ESMO Antiemetic Guideline 2013

MASCC/ESMO Antiemetic Guideline 2013 MASCC/ESMO Antiemetic Guideline 2013 Multinational Association of Supportive Care in Cancer Organizing and Overall Meeting Chairs: Richard J. Gralla, MD Fausto Roila, MD Maurizio Tonato, MD Jørn Herrstedt,

More information

THE HAZARDOUS WASTE (ENGLAND AND WALES) REGULATIONS 2005

THE HAZARDOUS WASTE (ENGLAND AND WALES) REGULATIONS 2005 THE HAZARDOUS WASTE (ENGLAND AND WALES) REGULATIONS 2005 Interim Guidance for the NHS Hospital Sector for England and Wales and Information for Scotland Additional paper copies may be requested by contacting:

More information

BREAST CANCER - METASTATIC & LOCALLY ADVANCED CHEMOTHERAPY REGIMENS Capecitabine. Capecitabine + Docetaxel. Capecitabine + Vinorelbine

BREAST CANCER - METASTATIC & LOCALLY ADVANCED CHEMOTHERAPY REGIMENS Capecitabine. Capecitabine + Docetaxel. Capecitabine + Vinorelbine Capecitabine Capecitabine 1000-1250mg/m 2 oral TWICE daily for 14 days Until disease progression Capecitabine + Docetaxel Capecitabine 750-1000mg/m 2 oral TWICE daily for 14 days Up to 6 cycles Capecitabine

More information

Medical Oncology Services and External Infusion Pumps. Part B Provider Outreach and Education February 2016

Medical Oncology Services and External Infusion Pumps. Part B Provider Outreach and Education February 2016 Medical Oncology Services and External Infusion Pumps Part B Provider Outreach and Education February 2016 DISCLAIMER This information release is the property of Noridian Healthcare Solutions, LLC. It

More information

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted

More information

Oncologic drug Exposure Risks and Prevention Guidelines 19 June 2014

Oncologic drug Exposure Risks and Prevention Guidelines 19 June 2014 Oncologic drug Exposure Risks and Prevention Guidelines 19 June 2014 ส งค กคามซ งอาจเป นอ นตรายต อส ขภาพ HAZARD? HAZARD ส งค กคามซ งอาจเป นอ นตรายต อส ขภาพ ENCLOSURE Substitution ส งค กคามซ งอาจเป นอ นตรายต

More information

Objectives PREVENTION AND TREATMENT OF CINV & VTE IN ONCOLOGY PATIENTS. Case 1. Case 1. Case 2 2/1/2015

Objectives PREVENTION AND TREATMENT OF CINV & VTE IN ONCOLOGY PATIENTS. Case 1. Case 1. Case 2 2/1/2015 Objectives PREVENTION AND TREATMENT OF CINV & VTE IN ONCOLOGY PATIENTS Jennifer Gallanger, Pharm.D. Jennifer Kubert, Pharm.D. Pharmacy Practice Residents Providence Alaska Medical Center Discuss the pathophysiology

More information

ASWCS Policy for the Treatment of Extravasation Injury

ASWCS Policy for the Treatment of Extravasation Injury ASWCS Policy for the Treatment of Extravasation Injury Extravasation of Cytotoxic Drugs Introduction 1. The purpose of this policy is to inform practitioners of their responsibilities in relation to preventing

More information

Chapter 7: Lung Cancer

Chapter 7: Lung Cancer Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin

More information

2006 CPT Coding and Documentation for Drug Administration

2006 CPT Coding and Documentation for Drug Administration 2006 CPT Coding and Documentation for Drug Administration Sheila Goethel, RHIT, CCS Rural WI Health Cooperative December 2005 Presentation Objectives Orient to new CPT drug administration codes Provide

More information

Coding Trends for Infusions and Injections. Injections

Coding Trends for Infusions and Injections. Injections Coding Trends for Infusions and Injections Lynn M. Anderanin, CPC,CPC I,COSC AHIMA Approved ICD 10 CM Trainer 1 Today s Agenda Infusions Injections Drugs 2 1 Infusions 3 categories of CPT codes for chemotherapy

More information

LTC Pharmacy Setting B/D Coverage. Because most LTC facilities are not considered a beneficiary s home 3

LTC Pharmacy Setting B/D Coverage. Because most LTC facilities are not considered a beneficiary s home 3 Medicare Parts Issues This table provides a reference guide for the most frequent B/D coverage determination scenarios facing Part D plans and Part D pharmacy providers. It does not address all potential.

More information

Guidelines for the Management of. Nausea and Vomiting in Cancer Patients

Guidelines for the Management of. Nausea and Vomiting in Cancer Patients Guidelines for the Management of Nausea and Vomiting in Cancer Patients Guidelines for the Management of Nausea and Vomiting in Cancer Patients Management of chemotherapy-induced nausea and vomiting includes

More information

Implications of dose rounding intravenous chemotherapy at a community based hospital

Implications of dose rounding intravenous chemotherapy at a community based hospital Implications of dose rounding intravenous chemotherapy at a community based hospital 1 2 ABSTRACT OBJECTIVES: To quantify and evaluate the total number of pharmacist interventions completed for dose rounding

More information

January 2004 Update of the Hospital Outpatient Prospective Payment System (OPPS)

January 2004 Update of the Hospital Outpatient Prospective Payment System (OPPS) January 2004 Update of the Hospital Outpatient Prospective Payment System (OPPS) This article outlines changes in the OPPS for calendar year 2004. These changes were discussed in the OPPS final rule for

More information

PHARMACY 1000.519 Effective Date Title: 10/12 HIGH-ALERT / HIGH-RISK / HAZARDOUS / LOOK ALIKE / SOUND ALIKE MEDICATIONS. Michele Goeb-Burkett 10/12

PHARMACY 1000.519 Effective Date Title: 10/12 HIGH-ALERT / HIGH-RISK / HAZARDOUS / LOOK ALIKE / SOUND ALIKE MEDICATIONS. Michele Goeb-Burkett 10/12 XXX DAYTONA XXX _OCEANSIDE XXX HEALTH CARE PARTNERS POLICY & PROCEDURE Department: Policy Number PHARMACY 1000.519 Effective Date Title: 10/12 HIGH-ALERT / HIGH-RISK / HAZARDOUS / LOOK ALIKE / SOUND ALIKE

More information

In this issue Page. anthem.com. Important phone numbers. May 2012

In this issue Page. anthem.com. Important phone numbers. May 2012 May 2012 In this issue Page Announcement Anthem rolls out Quality-In-Sights Program in Virginia 3 Use Provider Online Interactive Tool to view information regarding Anthem Quality-In-Sights 4 Coverage

More information

A guide for reluctant pharmacists

A guide for reluctant pharmacists PHARMACY REIMBURSEMENT A guide for reluctant pharmacists Anne T. Jarrett, MS, RPh Anne T. Jarrett, MS, RPh Assistant Director of Pharmacy Wake Forest University Baptist Hospital Winston-Salem, North Carolina

More information

Waste Management Policy

Waste Management Policy Sharepoint Location Non-clinical Policies and Guidelines Sharepoint Index Directory 3.0 Corporate Sub Area 3.2 Trustwide Management Key words (for search purposes) Waste, Hazardous, Sharps, Household Central

More information

DRUG DOSE CALCULATIONS

DRUG DOSE CALCULATIONS FINDING THE ORDERED DOSE The ordered dose is the most simple dosage calculation for the prehospital care provider. In this type of problem, the paramedic is given an order to administer to a patient. There

More information

Cytotoxic Therapy in Metastatic Breast Cancer

Cytotoxic Therapy in Metastatic Breast Cancer Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Version 2002: von Minckwitz Versions

More information

The N Factor: Prevention & Treatment of Chemotherapy-Induced Nausea & Vomiting

The N Factor: Prevention & Treatment of Chemotherapy-Induced Nausea & Vomiting The N Factor: Prevention & Treatment of Chemotherapy-Induced Nausea & Vomiting 45 TH ANNUAL GREAT LAKES CANCER NURSING CONFERENCE SOMERSET INN, TROY, MICHIGAN OCTOBER 2012 JOANNE P. MCGURN, BS PHARM, BCOP

More information

MEDICARE PART B CHEMOTHERAPY ADMINISTRATION: PAYMENT AND POLICY

MEDICARE PART B CHEMOTHERAPY ADMINISTRATION: PAYMENT AND POLICY Department of Health and Human Services OFFICE OF INSPECTOR GENERAL MEDICARE PART B CHEMOTHERAPY ADMINISTRATION: PAYMENT AND POLICY Daniel R. Levinson Inspector General June 2009 OEI-09-08-00190 Office

More information

Medical, Surgical, and Routine Supplies (including but not limited to 99070)

Medical, Surgical, and Routine Supplies (including but not limited to 99070) Manual: Policy Title: Reimbursement Policy Medical, Surgical, and Routine Supplies (including but not limited to 99070) Section: Administrative Subsection: none Date of Origin: 1/1/2002 Policy Number:

More information

Preventing and Treating Nausea and Vomiting Caused by Cancer Treatment

Preventing and Treating Nausea and Vomiting Caused by Cancer Treatment A Patient s Guide Preventing and Treating Nausea and Vomiting Caused by Cancer Treatment Recommendations of the American Society of Clinical Oncology The American Society of Clinical Oncology (ASCO) is

More information

SOUTH CENTRAL AMBULANCE SERVICE NHS FOUNDATION TRUST CORPORATE POLICY & PROCEDURE. No EPP20 WASTE MANAGEMENT. November 2015

SOUTH CENTRAL AMBULANCE SERVICE NHS FOUNDATION TRUST CORPORATE POLICY & PROCEDURE. No EPP20 WASTE MANAGEMENT. November 2015 SOUTH CENTRAL AMBULANCE SERVICE NHS FOUNDATION TRUST CORPORATE POLICY & PROCEDURE No EPP20 WASTE MANAGEMENT November 2015 DOCUMENT INFORMATION Author: Mike Kerrigan Head of Estates Consultation & Approval:

More information

A guide to cancer types and chemotherapy medications

A guide to cancer types and chemotherapy medications A guide to cancer types and chemotherapy medications This guides lists words that mean cancer, cancer types and intravenous chemotherapy medications. If you have any questions, see page 10 for details

More information

Basics of Systemic Anticancer Therapy Prescribing and Verification

Basics of Systemic Anticancer Therapy Prescribing and Verification CHAPTER 2 Basics of Systemic Anticancer Therapy Prescribing and Verification Trinh Pham Joan Rivington Learning Objectives Upon completion of the chapter, the reader will be able to: 1. Write clear and

More information

Classification of Hazardous Drugs by NIOSH

Classification of Hazardous Drugs by NIOSH Classification of Hazardous Drugs by NIOSH Thomas H. Connor, PhD Research Biologist National Institute for Occupational Safety and Health NIOSH Goals Protect workers from exposure to hazardous drugs Provide

More information

Medications or therapeutic solutions may be injected directly into the bloodstream

Medications or therapeutic solutions may be injected directly into the bloodstream Intravenous Therapy Medications or therapeutic solutions may be injected directly into the bloodstream for immediate circulation and use by the body. State practice acts designate which health care professionals

More information

2015/2016 Schedule of Home Medical Services and Fees for Approved Agencies

2015/2016 Schedule of Home Medical Services and Fees for Approved Agencies 2015/2016 Schedule of Home Medical Services and Fees for Approved Agencies Legislative Authority: Health Insurance Act (Standard Hospital Benefit) Regulations 1971- Section 3(xv) This schedule lists the

More information

D( desired ) Q( quantity) X ( amount ) H( have)

D( desired ) Q( quantity) X ( amount ) H( have) Name: 3 (Pickar) Drug Dosage Calculations Chapter 10: Oral Dosage of Drugs Example 1 The physician orders Lasix 40 mg p.o. daily. You have Lasix in 20 mg, 40 mg, and 80 mg tablets. If you use the 20 mg

More information

CODING 101: YOUR QUESTIONS ANSWERED

CODING 101: YOUR QUESTIONS ANSWERED CODING 101: YOUR QUESTIONS ANSWERED ION Community Counts Practice Effectiveness Web Series September 18, 2014 Risë Marie Cleland, Oplinc Inc. www.oplinc.com AMA CPT is a Registered Trademark of the AMA

More information

Filtration Guidelines for the Administration of Intravenous Medications UK Pharmacy Services Revised 8/2010

Filtration Guidelines for the Administration of Intravenous Medications UK Pharmacy Services Revised 8/2010 iltration Guidelines for the Administration of Intravenous Medications UK Pharmacy Services Revised 8/2010 SUMMARY O CHANGES: Green = Added from literature (Lexi-Comp, Micromedex, pkg inserts) Yellow =

More information

Cycle frequency: Every four weeks Total number of cycles: 6-8

Cycle frequency: Every four weeks Total number of cycles: 6-8 Fludarabine Low Grade non-hodgkin s Lymphoma and CLL Fludarabine 25mg/m 2 oral Days 1-5 Cycle frequency: Every four weeks Total number of cycles: 6-8 Anti-emetic group Low Prophylactic co-trimoxazole and

More information

Extravasation guidelines 2007. Implementation Toolkit

Extravasation guidelines 2007. Implementation Toolkit Extravasation guidelines 2007 Guidelines Implementation Toolkit Contents Extravasation guidelines 2007 Introduction to the Extravasation guidelines Introduction 4 Overall Goal 4 Specific Targets and Aims

More information

Acute Lymphoblastic Leukaemia

Acute Lymphoblastic Leukaemia 1 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 Protocol Acute Lymphoblastic Leukaemia Acute Lymphoblastic Leukaemia and Lymphoblastic Lymphoma UKALL

More information

Antiemetic Guidelines for Adult Patients Receiving Chemotherapy and Radiotherapy

Antiemetic Guidelines for Adult Patients Receiving Chemotherapy and Radiotherapy Antiemetic Guidelines f Adult Patients Receiving Chemotherapy and Radiotherapy Produced by Pinkie Chambers and Susanna Daniels University College Hospital NHS Foundation Trust November 2010 (Review date

More information

INSTRUCTIONS FOR REPORTING IMMUNIZATION SERVICES TO THIRD PARTY PAYERS (Billing Guide)

INSTRUCTIONS FOR REPORTING IMMUNIZATION SERVICES TO THIRD PARTY PAYERS (Billing Guide) INSTRUCTIONS FOR REPORTING IMMUNIZATION SERVICES TO THIRD PARTY PAYERS (Billing Guide) NOTE: All italicized words or phrases are defined at the end of this document. Adults (19 years of age and older)

More information

2004 Healthcare Common Procedure Coding System (HCPCS)

2004 Healthcare Common Procedure Coding System (HCPCS) Minnesota Health Care Programs (MHCP) Provider Update June 30, 2004 2004 Healthcare Common Procedure Coding System () This provider update informs providers of additions, changes and deletions to the national

More information

SAFE HANDLING OF HAZARDOUS MEDICATIONS. Cytotoxic and Non-Cytotoxic. Winnipeg Regional Health Authority Policy # 110.160.010

SAFE HANDLING OF HAZARDOUS MEDICATIONS. Cytotoxic and Non-Cytotoxic. Winnipeg Regional Health Authority Policy # 110.160.010 SAFE HANDLING OF HAZARDOUS MEDICATIONS Cytotoxic and Non-Cytotoxic Winnipeg Regional Health Authority Policy # 110.160.010 By the end of this presentation staff should be able to 1. Understand what information

More information

NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010

NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010 NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Institute for Occupational

More information

About chemotherapy for lung cancer

About chemotherapy for lung cancer About chemotherapy for lung cancer This information is about chemotherapy for lung cancer. There are sections on What is chemotherapy? Chemotherapy for small cell lung cancer Chemotherapy for non-small

More information

Outpatient Billing/Coding: A Focus on Missed Reimbursement & Quality of Reported Data

Outpatient Billing/Coding: A Focus on Missed Reimbursement & Quality of Reported Data Outpatient Billing/Coding: A Focus on Missed Reimbursement & Quality of Reported Data 438 e wilson bridge road, suite 200 worthington, oh 43085-2382 888-779-5663 www.cleverleyassociates.com 1 All US Average

More information

Subject: Bundled Services and Supplies

Subject: Bundled Services and Supplies Blue Cross and Blue Shield of Georgia Inc, and Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. (hereinafter referred to collectively as BCBSGA ) Professional Reimbursement Policy Subject: Bundled

More information

Distribution: Practitioner 01-04 Health Maintenance Organization 01-06. Medicaid, Children s Special Health Care Services, State Medical Program

Distribution: Practitioner 01-04 Health Maintenance Organization 01-06. Medicaid, Children s Special Health Care Services, State Medical Program Bulletin Michigan Department of Community Health Distribution: Practitioner 01-04 Health Maintenance Organization 01-06 Issued: April 1, 2001 Subject: Changes for Practitioners Related to Adoption of Uniform

More information

J_Code To NDC Billing Cross Reference Guide

J_Code To NDC Billing Cross Reference Guide J_Code To Billing Cross Reference Guide J0129 Injection, abatacept, 10 mg GENERIC J0129 UN 250 MG 250 MG 25 ABATACEPT/MALTOSE J0150 6 MG Injection adenosine 6 MG GENERIC J0150 ML 3 MG/ML 3 MG ML 1 0.5

More information

Medicare Drug Coverage Under Part A, Part B, and Part D

Medicare Drug Coverage Under Part A, Part B, and Part D Medicare Drug Coverage Under Part A, Part B, and Part D Medicare Part A and Part B generally do not cover outpatient prescription drugs, most of which are now covered under Part D. This document and the

More information

Cardiac Procedure: Outpatient Office Inpatient Emergent/Urgent Diagnostic Catheterization Required Required Not Not required

Cardiac Procedure: Outpatient Office Inpatient Emergent/Urgent Diagnostic Catheterization Required Required Not Not required Important Changes In Notification and Prior Authorization Procedures (This is revised from the article that was posted in the September 2012 Network Bulletin. Changes are in Section 3, Standardization

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007

More information

Empire BlueCross BlueShield Professional Reimbursement Policy

Empire BlueCross BlueShield Professional Reimbursement Policy Pressional Reimbursement Policy Subject: Bundled Services and Supplies NY Policy: 0008 Effective: 01/01/2014-02/23/2014 Coverage is subject to the terms, conditions, and limitations an individual member

More information

DRUG CALCULATIONS FOR REGISTERED NURSES ADULT SERVICES

DRUG CALCULATIONS FOR REGISTERED NURSES ADULT SERVICES Serving the people of north east Essex DRUG CALCULATIONS FOR REGISTERED NURSES ADULT SERVICES A Programmed Approach - It is essential you read this pack & practice the questions prior to your drug calculation

More information

Perioperative Charge Process

Perioperative Charge Process There are eight components to the charge process for surgical services: 1. Pre op prep and care 2. Anesthesia 3. Operating room time charges 4. Equipment charges 5. Recovery / Post Anesthesia Care Unit

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: infusion_therapy_in_the_home 3/1998 2/2016 2/2017 2/2016 Description of Procedure or Service Home infusion

More information

02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION REGULATIONS RELATING TO ADMINISTRATION OF INTRAVENOUS THERAPY BY LICENSED NURSES

02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION REGULATIONS RELATING TO ADMINISTRATION OF INTRAVENOUS THERAPY BY LICENSED NURSES 02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION 380 BOARD OF NURSING Chapter 10: REGULATIONS RELATING TO ADMINISTRATION OF INTRAVENOUS THERAPY BY LICENSED NURSES SUMMARY: This chapter identifies

More information

Re: Formal Request for NCD Reconsideration- Tumor Antigen by ImmunoassayCA125 (40-17)

Re: Formal Request for NCD Reconsideration- Tumor Antigen by ImmunoassayCA125 (40-17) May 9, 2005 Coverage and Analysis Group Centers for Medicare and Medicaid Services 7500 Security Blvd. (Mailstop C1-09-06) Baltimore, MD 21244 Re: Formal Request for NCD Reconsideration- Tumor Antigen

More information

Cycle frequency: Every three weeks Total number of cycles: 3 or 4

Cycle frequency: Every three weeks Total number of cycles: 3 or 4 BEP 3-day (Bleomycin/Etoposide/Cisplatin) Germ cell tumours Bleomycin 30,000iu 200mls N. Saline/30mins Days 2, 8 & 15 Etoposide 165mg/m 2 1L N. Saline/1hr Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/4hrs

More information

Drugs covered under Medicare Part B or Part D

Drugs covered under Medicare Part B or Part D LABEL_NAME GENERIC_NAME MESSAGE GEMZAR INJ 1 GM GEMCITABINE HCL FOR INJ 1 GM ALIMTA INJ 500MG PEMETREXED DISODIUM FOR IV SOLN 500 MG (BASE EQUIV) FUNGIZONE INJ 50MG AMPHOTERICIN B FOR INJ 50 MG KYTRIL

More information

University of Kentucky / UK HealthCare Policy and Procedure. Policy # A14-065

University of Kentucky / UK HealthCare Policy and Procedure. Policy # A14-065 University of Kentucky / UK HealthCare Policy and Procedure Policy # A14-065 Title/Description: Chemotherapy and Hazardous Medication Use Process Purpose: To standardize work processes that incorporate

More information

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY Original Issue Date (Created): 10/1/2014 Most Recent Review Date (Revised): 6/2/2015 Effective Date: 8/1/2015 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER

More information

Hazards of Cytotoxic Drugs

Hazards of Cytotoxic Drugs 38 H Y G E I A HYGEIA Vol.1, No.1 March-Aug, 09 Hazards of Cytotoxic Drugs 1 2 Kiron SS, Saritha M 1 Academy of Pharmaceutical Sciences, Medical College, Pariyaram, Kannur, Kerala. 2 Crescent College of

More information

Medication Calculation Practice Problems

Medication Calculation Practice Problems 1 Medication Calculation Practice Problems Dosage Calculation 1. The order is for 60 mg of furosemide (Lasix) po daily. Available to the nurse is Lasix 40 mg/tablet. The nurse would administer how many

More information

Administering Medications

Administering Medications Administering Medications Pharmacology for Healthcare Professionals seventh edition Donna F. Gauwitz, R.N., Nursing Consultant Senior Teaching Specialist of Nursing University of Minnesota Minnesota and

More information

Physician Coding and Payment Guide 2015

Physician Coding and Payment Guide 2015 Targeted Drug Delivery Physician Coding and Payment Guide 2015 Flowonix Medical has compiled this coding information for your convenience. This information is gathered from third party sources and is subject

More information

Medicare Part B versus Part D Coverage Issues DRAFT for Discussion Purposes Only Subject to Change revised 3/23/05

Medicare Part B versus Part D Coverage Issues DRAFT for Discussion Purposes Only Subject to Change revised 3/23/05 MEDICARE PART B VERSUS PART D COVERAGE ISSUES This document is not a statement or promise of coverage, but rather a discussion of when something may be covered under Parts A, B or D, if all other coverage

More information

Vaccination (Immunization)

Vaccination (Immunization) Policy Number IMM10012009SC Approved By Vaccination (Immunization) UnitedHealthcare Medicare Committee Current Approval Date 04/08/2015 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable

More information

2014-06-10 Approved Bendamustine - Treatment of relapsed low grade NHL in patients unable to receive standard therapy 2014-05-

2014-06-10 Approved Bendamustine - Treatment of relapsed low grade NHL in patients unable to receive standard therapy 2014-05- Sub. Sub. Status -06-16 Approved Lenalidomide - 2nd line treatment of multiple myeloma in patients who have contraindications to the use of bortezomib -06-16 Approved Lenalidomide - 2nd line treatment

More information

Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015

Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015 Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015 Advanced Refractory Solid Tumors or Lymphomas ECOG-ACRIN EAY131 (NCI CIRB) Targeted Therapy Directed by Genetic Testing in Treating

More information

Medicare Part B vs. Part D

Medicare Part B vs. Part D Medicare Part B vs. Part D 60889-R8-V1 (c) 2012 Amgen Inc. All rights reserved 2 This information is provided for your background education and is not intended to serve as guidance for specific coding,

More information

V: Infusion Therapy. Alberta Licensed Practical Nurses Competency Profile 217

V: Infusion Therapy. Alberta Licensed Practical Nurses Competency Profile 217 V: Infusion Therapy Alberta Licensed Practical Nurses Competency Profile 217 Competency: V-1 Knowledge of Intravenous Therapy V-1-1 V-1-2 V-1-3 V-1-4 V-1-5 Demonstrate knowledge and ability to apply critical

More information

2006 Provider Coding/Billing Information. www.novoseven-us.com

2006 Provider Coding/Billing Information. www.novoseven-us.com 2006 Provider Coding/Billing Information 2 3 Contents About NovoSeven...2 Coverage...4 Coding...4 Reimbursement...8 Establishing Medical Necessity and Appealing Denied Claims...10 Claims Materials...12

More information

2. Order: Nipride 500 mg IV in 250 ml D5w at 2 mcg/kg/min for a patient weighing 125 lb. Administer at ml/hr

2. Order: Nipride 500 mg IV in 250 ml D5w at 2 mcg/kg/min for a patient weighing 125 lb. Administer at ml/hr 1 Pharmacology Review Quiz: 1. Order: Xylocaine 1 g IV in 500 ml D5W at 3 mg/min. Set the infusion pump at ml/hr 2. Order: Nipride 500 mg IV in 250 ml D5w at 2 mcg/kg/min for a patient weighing 125 lb.

More information

[ ] POCT glucose Routine, As needed, If long acting insulin is given and patient NPO, do POCT glucose every 2 hours until patient eats.

[ ] POCT glucose Routine, As needed, If long acting insulin is given and patient NPO, do POCT glucose every 2 hours until patient eats. Glycemic Control - Insulin Infusion NOTE: For treatment of Diabetic Ketoacidosis or Hyperglycemic Hyperosmolar Syndrome please go to order set named Diabetic Ketoacidosis (DKA) and Hyperglycemic Hyperosmolar

More information

Coding for Vaccines and Immunization Administration in 2011: Major and Welcome Changes to the CPT 2011 Immunization Administration Codes

Coding for Vaccines and Immunization Administration in 2011: Major and Welcome Changes to the CPT 2011 Immunization Administration Codes Page 1 of 9 Print Close Window Coding for Vaccines and Immunization Administration in 2011: Major and Welcome Changes to the CPT 2011 Immunization Administration Codes November 2010 Pediatricians and pediatric

More information

TABLE OF CONTENTS. Home Infusion Therapy Guidelines... 2

TABLE OF CONTENTS. Home Infusion Therapy Guidelines... 2 TABLE OF CONTENTS Home Infusion Therapy Guidelines... 2 Services normally considered eligible for benefits... 2 Description... 2 Pre-certification Requirements... 3 Billing Guidelines... 3 Home Infusion

More information

Metastatic Breast Cancer - Pipeline Review, Q1 2011

Metastatic Breast Cancer - Pipeline Review, Q1 2011 Brochure More information from http://www.researchandmarkets.com/reports/1524592/ Metastatic Breast Cancer - Pipeline Review, Q1 2011 Description: Metastatic Breast Cancer - Pipeline Review, Q1 2011 Summary

More information

Chemotherapy Drugs: How They Work

Chemotherapy Drugs: How They Work Chemotherapy Drugs: How They Work Chemotherapy is the use of any drug (such as aspirin or penicillin) to treat any disease. But to most people, chemotherapy refers to drugs used for cancer treatment. It

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS

More information

Reconstitution of Solutions

Reconstitution of Solutions Chapter 12 Reconstitution of Solutions Reconstitution Process of mixing and diluting solutions Some medications supplied in powder form and must be mixed with liquid before administration Parts of Solutions

More information

PHENYLEPHRINE HYDROCHLORIDE INJECTION USP

PHENYLEPHRINE HYDROCHLORIDE INJECTION USP PRESCRIBING INFORMATION PHENYLEPHRINE HYDROCHLORIDE INJECTION USP 10 mg/ml Sandoz Canada Inc. Date of Preparation: September 1992 145 Jules-Léger Date of Revision : January 13, 2011 Boucherville, QC, Canada

More information

BULLETIN CHANGES AND CORRECTIONS TO THE MISSISSIPPI FEE SCHEDULE

BULLETIN CHANGES AND CORRECTIONS TO THE MISSISSIPPI FEE SCHEDULE Mississippi Workers Compensation Commission 1428 Lakeland Drive / Post Office Box 5300 Jackson, Mississippi 39296-5300 (601) 987-4268 http://www.mwcc.state.ms.us Mike Marsh, Chairman Barney J. Schoby,

More information

Immunization Coding and Billing Basics

Immunization Coding and Billing Basics Immunization Billing Project Webinar Session - II Immunization Coding and Billing Basics September 26, 2013 PRESENTED BY CHRIS PERKEY, RN, CMPE SENIOR CONSULTANT CONSULTING AND PRACTICE MANAGEMENT SERVICES

More information

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone

More information

Small cell Lung cancer New Chemotherapy options. Nicolas Mach, MD,PD

Small cell Lung cancer New Chemotherapy options. Nicolas Mach, MD,PD Small cell Lung cancer New Chemotherapy options Nicolas Mach, MD,PD > 40 negative Phase III trials List of unsucessful drugs Pemetrexed, imatinib, bevacizumab, bcl-2 antagonist, ASCT, CASE PRESENTATION

More information

Treating Mesothelioma - A Quick Guide

Treating Mesothelioma - A Quick Guide Treating Mesothelioma - A Quick Guide Contents This is a brief summary of the information on Treating mesothelioma from CancerHelp UK. You will find more detailed information on the website. In this information

More information

CHEMOTHERAPY PROTOCOLS V10.1

CHEMOTHERAPY PROTOCOLS V10.1 CHEMOTHERAPY PROTOCOLS V10.1 Issue Date: 10 th July 2014 Page 1 of 42 Filename: MCHACPROTO Issue No: 10.1 CCC Chemotherapy Protocols Haematological Malignancies... 3 Hodgkins disease...3 Non-Hodgkins Lymphoma...5

More information

Reimbursement for Physician- Administered Drugs:

Reimbursement for Physician- Administered Drugs: Reimbursement for Physician- Purchased and Physician- Administered Drugs: Understanding the Buy and Bill Process 60889-R5-V1 This information is provided d for your background education and is not intended

More information

Don t Let Money Go to Waste. Learn to Bill Discarded Drugs Correctly.

Don t Let Money Go to Waste. Learn to Bill Discarded Drugs Correctly. Don t Let Money Go to Waste. Learn to Bill Discarded Drugs Correctly. The Centers for Medicare & Medicaid Services (CMS) recently released Transmittal 1962 clarifying the use of modifier JW and how to

More information